Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?

Now more than ever is the time of monoclonal antibody use in neurology. In headaches, disease-specific and mechanism-based treatments existed only for symptomatic management of migraines (i.e., triptans), while the standard prophylactic anti-migraine treatments consist of non-specific and repurposed...

Descripción completa

Detalles Bibliográficos
Autores principales: Mavridis, Theodoros, Deligianni, Christina I., Karagiorgis, Georgios, Daponte, Ariadne, Breza, Marianthi, Mitsikostas, Dimos D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308667/
https://www.ncbi.nlm.nih.gov/pubmed/34358126
http://dx.doi.org/10.3390/ph14070700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308667/
https://www.ncbi.nlm.nih.gov/pubmed/34358126
http://dx.doi.org/10.3390/ph14070700

Ejemplares similares